Is monthly retreatment with intravitreal bevacizumab (Avastin(®)) necessary in neovascular age-related macular degeneration?

PURPOSE: To report our short-term experience with bevacizumab in neovascular age-related macular degeneration (AMD) and recommend a new treatment strategy. METHODS: Retrospective chart review of 29 consecutive patients receiving 1.25 mg of intravitreal bevacizumab for AMD and completing 12 weeks of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghazi, Nicola G, Kirk, Tyler Q, Knape, Robert M, Tiedeman, James S, Conway, Brian P
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861937/
https://www.ncbi.nlm.nih.gov/pubmed/20463798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861937/
https://www.ncbi.nlm.nih.gov/pubmed/20463798

Ejemplares similares